Saturday, 31 October 2026European Markets

ONWARD MEDICAL Stock Impressive Rise On Monday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with ONWARD MEDICAL (ONWD.BR) rising 11.96% to €6.18 on Monday while BEL 20 fell 0.3% to €3,673.19.

ONWARD MEDICAL's last close was €5.52, 16.11% below its 52-week high of €6.58.

About ONWARD MEDICAL

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.2.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -69.93%.

Volume

Today's last reported volume for ONWARD MEDICAL is 136248 which is 46.6% above its average volume of 92938.

Yearly Top and Bottom Value

ONWARD MEDICAL's stock is valued at €6.18 at 21:33 EST, below its 52-week high of €6.58 and way higher than its 52-week low of €1.85.

Volatility

ONWARD MEDICAL's last week, last month's, and last quarter's current intraday variation average was a negative 3.41%, a positive 0.03%, and a positive 6.92%.

ONWARD MEDICAL's highest amplitude of average volatility was 4.33% (last week), 5.58% (last month), and 6.92% (last quarter).

Moving Average

ONWARD MEDICAL's worth is way above its 50-day moving average of €4.16 and way above its 200-day moving average of €4.15.

More news about ONWARD MEDICAL (ONWD.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com